Abstract
This report describes initial results with a new pump-oxygenator circuit. The circuit has a low priming volume and the components are small enough that the entire system can be positioned in close proximity to the patient. The net result is substantially decreased hemodilution. The effect of the heparin-coated surfaces and oxygenator design on decreasing complement activation and other immunologically-mediated adverse events was not directly evaluated.Although this small series did not provide data robust enough to recommend routine use of the system, the data are sufficiently interesting to stimulate further investigation. Of note, the authors mentioned several potential complications of the MECC system that are serious and might prove fatal. These include air embolism and sudden decrease or loss of flow due to interruption of venous inflow in the absence of a venous reservoir. It is also clear from this report that a dedicated team effort is needed to use this system safely and effectively.The balance of benefit to risk as well as cost for the MECC system versus conventional CPB or off-pump techniques remains to be clearly defined, as do its indications for use. Results of this system used in patients who are at risk for the adverse effects of CPB (eg, adults with severe pulmonary disease or infants) will be particularly interesting. This report describes initial results with a new pump-oxygenator circuit. The circuit has a low priming volume and the components are small enough that the entire system can be positioned in close proximity to the patient. The net result is substantially decreased hemodilution. The effect of the heparin-coated surfaces and oxygenator design on decreasing complement activation and other immunologically-mediated adverse events was not directly evaluated. Although this small series did not provide data robust enough to recommend routine use of the system, the data are sufficiently interesting to stimulate further investigation. Of note, the authors mentioned several potential complications of the MECC system that are serious and might prove fatal. These include air embolism and sudden decrease or loss of flow due to interruption of venous inflow in the absence of a venous reservoir. It is also clear from this report that a dedicated team effort is needed to use this system safely and effectively. The balance of benefit to risk as well as cost for the MECC system versus conventional CPB or off-pump techniques remains to be clearly defined, as do its indications for use. Results of this system used in patients who are at risk for the adverse effects of CPB (eg, adults with severe pulmonary disease or infants) will be particularly interesting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.